Luise Linsenmeier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Luise Linsenmeier has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Hermann Clemens Altmeppen
Institute of Neuropathology University Medical Center Hamburg‐Eppendorf (UKE) Hamburg Germany
4 shared publications - Markus Glatzel
Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
4 shared publications - Behnam Mohammadi
Institute of Neuropathology University Medical Center Hamburg‐Eppendorf (UKE) Hamburg Germany
3 shared publications - Berta Puig
Neurology Department Experimental Research in Stroke and Inflammation (ERSI) University Medical Center Hamburg‐Eppendorf Hamburg Germany
3 shared publications - Jörg Tatzelt
Department Biochemistry of Neurodegenerative Diseases Institute of Biochemistry and Pathobiochemistry Ruhr University Bochum 44801 Bochum Germany
2 shared publications - Mohsin Shafiq
Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
2 shared publications
Latest Publications
- Open Access
- 26 November 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (48)
Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies
Ligand-stimulated enzymatic release or cellular degradation of PrP may interfere with neurodegeneration-associated toxicity.
- 26 November 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (48)
Open AccessLigands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies
Ligand-stimulated enzymatic release or cellular degradation of PrP may interfere with neurodegeneration-associated toxicity.
- Open Access
- 4 May 2020
- Published by Springer Nature in Molecular Neurobiology
- Vol. 57 (6) , 2812-2829
Transgenic Overexpression of the Disordered Prion Protein N1 Fragment in Mice Does Not Protect Against Neurodegenerative Diseases Due to Impaired ER Translocation
The structurally disordered N-terminal half of the prion protein (PrPC) is constitutively released into the extracellular space by an endogenous proteolytic cleavage event. Once liberated, this N1 fragment acts neuroprotective in ischemic conditions and interferes with toxic peptides associated with neurodegenerative diseases, such as amyloid-beta (Aβ) in Alzheimer’s disease. Since analog protective effects of N1 in prion diseases, such as Creutzfeldt-Jakob disease, have not been studied, and given that the protease releasing N1 has not been identified to date, we have generated and characterized transgenic mice overexpressing N1 (TgN1). Upon intracerebral inoculation of TgN1 mice with prions, no protective effects were observed at the levels of survival, clinical course, neuropathological, or molecular assessment. Likewise, primary neurons of these mice did not show protection against Aβ toxicity. Our biochemical and morphological analyses revealed that this lack of protective effects is seemingly due to an impaired ER translocation of the disordered N1 resulting in its cytosolic retention with an uncleaved signal peptide. Thus, TgN1 mice represent the first animal model to prove the inefficient ER translocation of intrinsically disordered domains (IDD). In contrast to earlier studies, our data challenge roles of cytoplasmic N1 as a cell penetrating peptide or as a potent “anti-prion” agent. Lastly, our study highlights both the importance of structured domains in the nascent chain for proteins to be translocated and aspects to be considered when devising novel N1-based therapeutic approaches against neurodegenerative diseases.
- 4 May 2020
- Published by Springer Nature in Molecular Neurobiology
- Vol. 57 (6) , 2812-2829
Open AccessTransgenic Overexpression of the Disordered Prion Protein N1 Fragment in Mice Does Not Protect Against Neurodegenerative Diseases Due to Impaired ER Translocation
The structurally disordered N-terminal half of the prion protein (PrPC) is constitutively released into the extracellular space by an endogenous proteolytic cleavage event. Once liberated, this N1 fragment acts neuroprotective in ischemic conditions and interferes with toxic peptides associated with neurodegenerative diseases, such as amyloid-beta (Aβ) in Alzheimer’s disease. Since analog protective effects of N1 in prion diseases, such as Creutzfeldt-Jakob disease, have not been studied, and given that the protease releasing N1 has not been identified to date, we have generated and characterized transgenic mice overexpressing N1 (TgN1). Upon intracerebral inoculation of TgN1 mice with prions, no protective effects were observed at the levels of survival, clinical course, neuropathological, or molecular assessment. Likewise, primary neurons of these mice did not show protection against Aβ toxicity. Our biochemical and morphological analyses revealed that this lack of protective effects is seemingly due to an impaired ER translocation of the disordered N1 resulting in its cytosolic retention with an uncleaved signal peptide. Thus, TgN1 mice represent the first animal model to prove the inefficient ER translocation of intrinsically disordered domains (IDD). In contrast to earlier studies, our data challenge roles of cytoplasmic N1 as a cell penetrating peptide or as a potent “anti-prion” agent. Lastly, our study highlights both the importance of structured domains in the nascent chain for proteins to be translocated and aspects to be considered when devising novel N1-based therapeutic approaches against neurodegenerative diseases.
- 1 November 2017
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1864 (11) , 2128-2137
Diverse functions of the prion protein – Does proteolytic processing hold the key?
- 1 November 2017
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1864 (11) , 2128-2137
Diverse functions of the prion protein – Does proteolytic processing hold the key?
- Open Access
- 4 July 2015
- Published by Taylor & Francis in Prion
- Vol. 9 (4) , 244-256
Shedding light on prion disease
Proteolytic processing regulates key processes in health and disease. The cellular prion protein (PrPC) is subject to at least 3 cleavage events, α-cleavage, β-cleavage and shedding. In contrast to α- and β-cleavage where there is an ongoing controversy on the identity of relevant proteases, the metalloprotease ADAM10 represents the only relevant PrP sheddase. Here we focus on the roles that ADAM10-mediated shedding of PrPC and its pathogenic isoform (PrPSc) might play in regulating their physiological and pathogenic functions, respectively. As revealed by our recent study using conditional ADAM10 knockout mice (Altmeppen et al., 2015 Altmeppen HC , Prox J , Krasemann S , Puig B , Kruszewski K , Dohler F , Bernreuther C , Hoxha A , Linsenmeier L , Sikorska B , et al. The sheddase ADAM10 is a potent modulator of prion disease. eLife 2015; 4; PMID:25654651; doi:10.7554/eLife.04260 [Crossref], [PubMed], [Web of Science ®] [Google Scholar] ), shedding of PrP seems to be involved in key processes of prion diseases. These aspects and several open questions arising from them are discussed. Increased knowledge on this topic can shed new light on prion diseases and other neurodegenerative conditions as well.
- 4 July 2015
- Published by Taylor & Francis in Prion
- Vol. 9 (4) , 244-256
Open AccessShedding light on prion disease
Proteolytic processing regulates key processes in health and disease. The cellular prion protein (PrPC) is subject to at least 3 cleavage events, α-cleavage, β-cleavage and shedding. In contrast to α- and β-cleavage where there is an ongoing controversy on the identity of relevant proteases, the metalloprotease ADAM10 represents the only relevant PrP sheddase. Here we focus on the roles that ADAM10-mediated shedding of PrPC and its pathogenic isoform (PrPSc) might play in regulating their physiological and pathogenic functions, respectively. As revealed by our recent study using conditional ADAM10 knockout mice (Altmeppen et al., 2015 Altmeppen HC , Prox J , Krasemann S , Puig B , Kruszewski K , Dohler F , Bernreuther C , Hoxha A , Linsenmeier L , Sikorska B , et al. The sheddase ADAM10 is a potent modulator of prion disease. eLife 2015; 4; PMID:25654651; doi:10.7554/eLife.04260 [Crossref], [PubMed], [Web of Science ®] [Google Scholar] ), shedding of PrP seems to be involved in key processes of prion diseases. These aspects and several open questions arising from them are discussed. Increased knowledge on this topic can shed new light on prion diseases and other neurodegenerative conditions as well.